What is Prostamax?
Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP), part of the tissue-specific short-peptide bioregulator family. Its prostate focus is distinct from its broader laboratory work on cell aging.[1][13]
Some experiments examine chromatin, the DNA-and-protein packaging inside the nucleus. Others examine prostate-cell signaling or experimental prostate disease in rats. These are different ways of studying cell activity, rather than one demonstrated clinical effect.[1][6][7]
A defined KEDP tetrapeptide differs from a prostate-tissue extract or a mixed supplement. Product names and prostate-related marketing do not establish the same composition as the material used in an experiment.[13][16]
What Prostamax is investigated for
Prostamax evidence is grouped by practical use case and oral, intramuscular, and rectal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Evidence snapshot
Overall confidence
Preclinical findings support interest in prostate-cell activity. Clinical symptom benefits, dependable dosing and long-term safety remain uncertain.[1][8][17]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Clinical benefits for urinary symptoms remain unestablished.[16][17][1]
Animal / preclinical
Preclinical work concerns chromatin organization and cell activity.[1][2][3][4][5][6]
Mechanism support
KEDP may influence chromatin, the DNA-and-protein packaging that helps regulate gene accessibility.[1]
Forms & administration
Prostamax has oral capsules and lingual drops. Proposed intramuscular and rectal suppository formulations remain experimental, with separate preparation and amounts.[13][14][16][17]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Typical Range
Oral capsule and drop strengths are not standardized. Rectal patent sections give conflicting peptide amounts.[13][17]
Frequency
The rectal patent describes one suppository daily; its strength discrepancy prevents a dependable dose specification.[17]
Timing Considerations
A reproducible clock-time or meal-timing anchor is not established across the oral and patent preparations.[13][16]
Cycle Length
Injection and suppository patent examples describe 10–40 days, rather than a standardized clinical course.[16][17]
Safety profile
Controlled human safety data are lacking. Unresolved dose-unit conflicts in the rat reports and suppository patent make dose comparisons particularly unreliable.[7][8][17]
Regulatory status
United States
Prostamax is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[15]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved Prostamax is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[15] | Not Reviewed Compounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions. |
Oral
FDA drug approval
Not ApprovedProstamax is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[15]
503A compounding
Not ReviewedCompounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions.
International
Medicinal-product authorization outside the United States remains unconfirmed for the named preparation; status depends on the exact product and country.[15]
Sports & competition
WADA S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no later section addresses them. An unapproved peptide preparation is not athlete-cleared.
How it works
KEDP may influence chromatin, the DNA-and-protein packaging that helps regulate which genes are accessible. This provides one possible link to cellular aging and maintenance.[1]
Proposed prostate-related actions involve cell growth, tissue maintenance and inflammatory signaling. A prostate-specific clinical target remains unconfirmed.[6][7][9]
Research gaps & open questions
What the current literature has not yet settled about Prostamax:
Independent controlled trials need to measure urinary symptoms, flow and quality of life. Cell and rat findings cannot establish whether people with prostate enlargement or prostatitis benefit.[7][8]
The conflicting units in rat studies and suppository patent examples need clarification using original formulation records, so that exposure can be compared without a 1,000-fold error.[7][8][17]
Human studies need to identify which capsule, drop or injectable products contain the same KEDP material, how much is absorbed and what adverse effects occur with repeated use.[13][16]
Common questions
Has Prostamax been shown to relieve urinary symptoms?
History & discovery
Prostamax research connects the short-peptide gene-regulation program with prostate-tissue models. Its published cellular evidence and inventor patent examples need to be distinguished from clinical treatment trials.[3][16]
Experiments examined short peptides in cells from older adults and later identified KEDP as Prostamax. Their chromosome and metabolic measurements concerned cell behavior rather than symptom relief.[3][1]
Separate reports examined prostatitis and prostate enlargement in rats. Their printed doses differ by 1,000-fold, leaving an unresolved unit discrepancy that prevents a dependable dose comparison.[7][8]
17 citations
Prostamax research focuses on prostate-cell activity, inflammation and age-related cellular changes. Clinical symptom benefits remain unestablished, and conflicting preparation strengths leave dosing uncertain.[1][7][8][17]
